Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor
Most Cited Paper
in Pediatric health and respiratory diseases
18 Months Post-Publication
Class of 2026
“Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/pediatric-health-and-respiratory-diseases/2026/
Topics
Elexacaftor/tezacaftor/ivacaftor · F508del mutation · CFTR modulator therapy · Pediatric cystic fibrosis cohort · Multicenter cohort study · Adverse events · CFTR modulator safety monitoring
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Pediatric health and respiratory diseases Papers, Class of 2026. https://pri.pepkio.com/top-papers/pediatric-health-and-respiratory-diseases/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459